PERK Inhibition Mitigates Restenosis and Thrombosis
Bowen Wang, Mengxue Zhang, Go Urabe, Yitao Huang, Guojun Chen, Debra G. Wheeler, David J. Dornbos, Allyson Huttinger, Shahid M. Nimjee, Shaoqin Gong, Lian‐Wang Guo, K. Craig Kent
Abstract
Developing endothelial-protective, nonthrombogenic antirestenotic treatments has been a challenge. A major hurdle to this has been the identification of a common molecular target in both smooth muscle cells and endothelial cells, inhibition of which blocks dysfunction of both cell types. The authors' findings suggest that the PERK kinase could be such a target. Importantly, PERK inhibition mitigated both restenosis and thrombosis in preclinical models, implicating a low-thrombogenic antirestenotic paradigm.
Topics & Concepts
RestenosisThrombosisMedicineSmooth muscleEndothelial dysfunctionEndothelial stem cellCancer researchPharmacologyCardiologyInternal medicineBiologyIn vitroStentBiochemistryRetinal Diseases and TreatmentsProtein Kinase Regulation and GTPase SignalingGlaucoma and retinal disorders